MSTN and rheumatoid arthritis: Due to the potential role that myostatin has as a biomarker in future studies, it is important to conduct more studies that allow us to understand the behavior of this molecule in patients with RA, allowing us to able to create drugs that act on the myostatin signaling pathway, with the precise dose to be able to counteract the harmful effects, without eliminating the muscle turnover effects and other side effects that may occur.